Mohamed Vall Mohamed Abdellahi

Dr. Mohamed Vall Mohamed Abdellahi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
MAMariem Salma Lejwad Abdoudaim
Mariem Salma Lejwad Abdoudaim
MAMohamed Vall Mohamed Abdellahi
Mohamed Vall Mohamed Abdellahi
NBNacer dine Mohamed Baba
Nacer dine Mohamed Baba
RBRalph Sydney Mboumba Bouassa
Ralph Sydney Mboumba Bouassa
Mohamed Lemine Cheikh Brahim AHMEDMohamed Lemine Cheikh Brahim AHMED
Mohamed Lemine Cheikh Brahim AHMED
LBLaurent Bélec
Laurent Bélec
Cervical cancer related to high-risk human papillomavirus (HR-HPV) is the second female cancer in Mauritania (Northwest Sahelian Africa). We assessed the distribution of HPV genotypes in Mauritanian women with high-grade cervical intraepithelial neoplasia (CIN2/3) or invasive cervical cancer (ICC). A prospective study was conducted in the Centre Hospitalier National, Nouakchott, Mauritania, to collect cervical biopsies among women suspected of CIN2/3 or cancer. HPV DNA detection and genotyping were carried out from formalin-fixed, paraffin-embedded biopsies using multiplex PCR (Human Papillomavirus Genotyping Real-Time PCR Kit, Bioperfectus Technologies Co., Taizhou, China). Fifty biopsies were included from women (mean age: 56.7 years) suffering from CIN2/3 (28.0%) and ICC (72.0%) which corresponded to 32 (64.0%) squamous cell carcinomas (SCC) and 4 (8.0%) adenocarcinomas (ADC). HPV DNA detection was successful in 47 (94.0%) samples. The most prevalent HR-HPV genotypes were HPV-45 (40.4%), HPV-16 (38.3%), HPV-39 and HPV-52 (23.4%), HPV-33 (17.0%), HPV-18 (14.9%), HPV-35 (4.2%), and HPV-56 (2.1%). The majority (93.6%) of HPV-positive biopsies contained at least one HPV type covered by the 9-valent Gardasil-9® vaccine, and 40.9% were infected by multiple vaccine HPV genotypes. To eradicate cervical cancer in Mauritania, prophylactic HPV vaccination must be combined with primary molecular screening of cervical HR-HPV infection.

1 April 2024 in Journal of Ecological Engineering
Verified
Journal Article
Open access
MMMoulaye M'Hamed Abdel Maleck
Moulaye M'Hamed Abdel Maleck
MZMohamed Lemine Cheikh Zamel
Mohamed Lemine Cheikh Zamel
CECherif Ahmed Ahmed Elmamy
Cherif Ahmed Ahmed Elmamy
DBDriss BELGHYTI
Driss BELGHYTI
MAMohamed Vall Mohamed Abdellahi
Mohamed Vall Mohamed Abdellahi
The objective of this study was to conduct a preliminary assessment of the potential impacts of effluents from freezing plants and fishmeal and oil factories in the Levrier Bay on the aquatic environment through physicochemical and microbiological characterization. Effluent samples from various...

12 February 2026 in Diseases
Verified
Journal Article
Open access
PDF file
MAMo Abdawa
Mo Abdawa
MHMohamed Hemeyine
Mohamed Hemeyine
Isabelle CheminIsabelle Chemin
Isabelle Chemin
FLFrançoise Lunel-Fabiani
Françoise Lunel-Fabiani
MAMohamed Vall Mohamed Abdellahi
Mohamed Vall Mohamed Abdellahi
Background: Hepatitis B virus (HBV) infection remains highly endemic in sub-Saharan Africa, where hepatitis delta virus (HDV) co-infection substantially worsens liver disease outcomes. Mauritania has long been suspected to be a high-burden setting for HBV-HDV co-infection, yet contemporary data describing its clinical and virological impact remain limited. Methods: We conducted a hospital-based cross-sectional study at the National Institute of Hepato-Virology (INHV) in Nouakchott, including 401 HBsAg-positive patients. Demographic, clinical, biological, and virological data were collected. HDV serology and RNA testing were performed when available. Liver disease severity, including cirrhosis and hepatocellular carcinoma (HCC), was assessed using clinical, biological, and imaging criteria. Results: HDV antibodies were detected in 31.9% of HBsAg-positive patients, confirming Mauritania as a hyper-endemic area for HDV. HDV co-infection was strongly associated with advanced liver disease, with HDV antibodies present in 86.4% of cirrhotic patients and 82.4% of those with HCC. Patients with HDV infection frequently exhibited suppressed HBV DNA levels, reflecting viral interference. A substantial proportion of patients presented with decompensated cirrhosis or HCC at diagnosis, and nearly 70% were treatment-naïve. Overall, HDV co-infection emerged as the principal driver of severe liver disease in this cohort. Conclusions: HBV/HDV co-infection is highly prevalent in Mauritania and is associated with a wide clinical spectrum ranging from asymptomatic infection to decompensated cirrhosis and hepatocellular carcinoma. HDV co-infection is the principal driver of severe liver disease, often occurring despite low or undetectable HBV DNA levels. Systematic HDV screening among all HBsAg-positive individuals is urgently needed to improve risk stratification, guide therapeutic decisions, and reduce liver-related morbidity and mortality.